<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082276</url>
  </required_header>
  <id_info>
    <org_study_id>D1050270</org_study_id>
    <nct_id>NCT01082276</nct_id>
  </id_info>
  <brief_title>Rifampin Drug-Drug Interaction Study With Lurasidone HCl</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of rifampin on the pharmacokinetics of lurasidone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      by performing an open-label, 2-period, sequential study in healthy subjects. All subjects
      (N=20) will be assigned to the same treatment sequence, 40 mg po dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Male, Healthy Normal Subjects</condition>
  <arm_group>
    <arm_group_label>Rifampin/Lurasidone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Normal Subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone HCl</intervention_name>
    <description>40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).</description>
    <arm_group_label>Rifampin/Lurasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female subjects must be of nonchildbearing potential (surgically sterile [hysterectomy
             or bilateral tubal ligation] or post-menopausal â‰¥ 1 year) with follicle stimulating
             hormone [FSH] &gt; 40 U/L).

          2. Subjects with partners of child-bearing potential must agree to use barrier
             contraception during the study and for 90 days after discharge. Volunteers must agree
             to not donate sperm during the study and for 90 days after discharge.

        Exclusion Criteria:

          1. Any disorder that would interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          2. Use of concomitant medications that prolong the QT/QTc interval from 14 days prior to
             day - 2 to discharge.

          3. Use of any inhibitor or inducer of CYP3A4 taken within 30 days prior to study Day -2

          4. Use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever was
             longer) prior to Screening.

          5. Previous exposure to lurasidone (SM-13496).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Clinical Pharmacology Research Unit at Baltimore, MD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL Clinical Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>September 6, 2011</last_update_submitted>
  <last_update_submitted_qc>September 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifampin DDI with Lurasidone HCl</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

